NO20050355L - IL-7 drug substance, il-7 comprising composition, preparation and uses thereof - Google Patents

IL-7 drug substance, il-7 comprising composition, preparation and uses thereof

Info

Publication number
NO20050355L
NO20050355L NO20050355A NO20050355A NO20050355L NO 20050355 L NO20050355 L NO 20050355L NO 20050355 A NO20050355 A NO 20050355A NO 20050355 A NO20050355 A NO 20050355A NO 20050355 L NO20050355 L NO 20050355L
Authority
NO
Norway
Prior art keywords
drug
drug substance
product
preparation
well
Prior art date
Application number
NO20050355A
Other languages
English (en)
Other versions
NO332305B1 (no
Inventor
Michel Christian Morre
Brigitte Assouline
Pierre Cortez
Anne Gregoire
Original Assignee
Cytheris
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytheris filed Critical Cytheris
Publication of NO20050355L publication Critical patent/NO20050355L/no
Publication of NO332305B1 publication Critical patent/NO332305B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5418—IL-7
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Transplantation (AREA)
  • AIDS & HIV (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Den foreliggende oppfinnelse vedrører generelt områdene immunologi og molekylær biologi. Ifølge oppfinnelsen beskrives nærmere bestemt interieukin-7-legemiddelsubstanser, korresponderende, spesifikke immunreaktive antistoffer samt preparater som inneholder samme, samt fremstilling og anvendelser derav. Ifølge oppfinnelsen beskrives også fremgangsmåter til å karakterisere forurensningsprofilen i en r-hiL-7-legemiddelsubstans anvendt for terapeutiske formål, samt optimaliserte nukleotidsekvenser som koder for pattedyr-IL-7, rekombinante ekspresjonsvektorer samt fremgangsmåter til fremstilling og rensing av polypeptidene. Oppfinnelsen er basert på den uventede iakttakelse at langtidsaktiviteten til rekombinant IL-7 for det meste uttrykkes av en spesifikk conformer og at andre conformere, potensielle produktrelaterte substanser, produktrelaterte forurensninger og prosessrelaterte forurensninger, som normalt ville være inkludert i legemiddelsubstansen og/eller legemiddelproduktet bør, selv om de er bioaktive minimaliseres strengt pga. at de er i stand til å utløse en immunreaksjon mot det ønskede IL-7-molekyl.
NO20050355A 2002-08-08 2005-01-25 IL-7 -legemiddelsubstans, preparat, samt fremstilling og anvendelse derav NO332305B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP02291996A EP1391513A1 (en) 2002-08-08 2002-08-08 IL-7 drug substance, IL-7 comprising composition, preparation and uses thereof
US47588103P 2003-06-05 2003-06-05
PCT/EP2003/008701 WO2004018681A2 (en) 2002-08-08 2003-08-06 Il-7 drug substance, il- 7 comprising composition, preparation and uses thereof

Publications (2)

Publication Number Publication Date
NO20050355L true NO20050355L (no) 2005-05-06
NO332305B1 NO332305B1 (no) 2012-08-20

Family

ID=30775891

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20050355A NO332305B1 (no) 2002-08-08 2005-01-25 IL-7 -legemiddelsubstans, preparat, samt fremstilling og anvendelse derav

Country Status (17)

Country Link
US (1) US7585947B2 (no)
EP (2) EP1391513A1 (no)
JP (3) JP2005534339A (no)
AT (1) ATE482273T1 (no)
AU (1) AU2003250216B2 (no)
CA (1) CA2494974C (no)
CY (1) CY1110994T1 (no)
DE (1) DE60334301D1 (no)
DK (1) DK1527179T3 (no)
ES (1) ES2353006T3 (no)
IL (1) IL166543A (no)
NO (1) NO332305B1 (no)
PL (1) PL213710B1 (no)
PT (1) PT1527179E (no)
SI (1) SI1527179T1 (no)
WO (1) WO2004018681A2 (no)
ZA (1) ZA200501914B (no)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE516820T1 (de) 2000-09-29 2011-08-15 Schering Corp Pegyliertes interleukin 10
CA2487673C (en) * 2003-12-02 2010-11-02 F. Hoffmann-La Roche Ag Improved method for the recombinant production and purification of protein kinases
PT1699822E (pt) 2003-12-30 2008-07-30 Merck Patent Gmbh Proteínas de fusão de il-7
EP1746161A1 (en) * 2005-07-20 2007-01-24 Cytheris Glycosylated IL-7, preparation and uses
CA2619989C (en) * 2005-08-23 2014-06-17 National Research Council Of Canada Regulation of heterologous recombinant protein expression in methylotrophic and methanotrophic bacteria
EP2032695B1 (en) 2006-05-31 2018-08-15 The Regents of The University of California Cd127 expression inversely correlates with foxp3 and suppressive function of cd4+ tregs
NZ597098A (en) 2006-09-28 2013-05-31 Merck Sharp & Dohme Use of pegylated il-10 to treat cancer
EP2649094B1 (en) 2010-12-10 2016-04-27 University of Central Florida Research Foundation, Inc. Methods and compositions comprising il-7 receptor ligands
AU2012292032A1 (en) 2011-08-03 2014-03-13 Cytheris HCV immunotherapy
BR112014026407B1 (pt) * 2012-04-23 2020-12-22 Bharat Biotech International Limited formulação de vacina líquida
RU2562169C2 (ru) * 2012-10-29 2015-09-10 Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт особо чистых биопрепаратов" Федерального медико-биологического агентства Штамм культивируемых клеток cho-il7/13 - продуцент интерлейкина-7 человека
CN105209054A (zh) 2013-04-18 2015-12-30 阿尔莫生物科技股份有限公司 使用白细胞介素-10治疗疾病和病症的方法
JP2016528879A (ja) 2013-06-17 2016-09-23 アルモ・バイオサイエンシーズ・インコーポレイテッド タンパク質の同一性および安定性を評価する方法
US11413332B2 (en) 2013-11-11 2022-08-16 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
WO2015140751A1 (en) 2014-03-21 2015-09-24 Boreal Invest Terminal nanofiltration of solubilized protein compositions for removal of immunogenic aggregates
US10293043B2 (en) 2014-06-02 2019-05-21 Armo Biosciences, Inc. Methods of lowering serum cholesterol
JP6675394B2 (ja) 2014-10-22 2020-04-01 アルモ・バイオサイエンシーズ・インコーポレイテッド 疾患及び障害の治療のためにインターロイキン−１０を使用する方法
US10618970B2 (en) 2015-02-03 2020-04-14 Armo Biosciences, Inc. Method of treating cancer with IL-10 and antibodies that induce ADCC
US20160361415A1 (en) 2015-05-28 2016-12-15 Armo Biosciences, Inc. Methods of Using Interleukin-10 for Treating Diseases and Disorders
RU2708160C2 (ru) * 2015-06-11 2019-12-04 Дженексин, Инк. Модифицированный белок интерлейкина-7 и способы его применения
KR102386735B1 (ko) 2015-11-06 2022-04-14 주식회사 제넥신 변형된 인터루킨-7 융합 단백질의 제형
RU2615447C1 (ru) * 2015-11-13 2017-04-04 Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт особо чистых биопрепаратов" Федерального медико-биологического агентства Синтетическая ДНК, кодирующая интерлейкин-7 человека, содержащий ее экспрессионный вектор (варианты), штамм-продуцент интерлейкина-7 человека и способ получения интерлейкина-7 человека
KR20170066265A (ko) 2015-12-04 2017-06-14 주식회사 제넥신 면역글로불린 Fc가 융합된 인터루킨-7 융합 단백질을 포함하는 사람 파필로마바이러스 유래 질환의 예방 또는 치료용 약학적 조성물
KR102604595B1 (ko) * 2015-12-04 2023-11-21 주식회사 제넥신 면역글로불린 Fc가 융합된 인터루킨-7 융합 단백질을 포함하는 인플루엔자 바이러스 감염의 예방 또는 치료용 약학적 조성물
WO2018156649A1 (en) * 2017-02-22 2018-08-30 Flagship Pioneering, Inc. Compositions of t cell modulator (tcm) molecules and uses thereof
CN113365650A (zh) 2018-11-16 2021-09-07 新免疫技术有限公司 用il-7蛋白和免疫检查点抑制剂的组合治疗肿瘤的方法
CN113614109A (zh) 2018-12-21 2021-11-05 Ose免疫疗法公司 双功能抗pd-1/il-7分子
AU2020383176B2 (en) * 2019-11-15 2023-10-19 Genexine, Inc. Fusion protein including modified interleukin-7 and TGF beta receptor II and use thereof
US20230057939A1 (en) 2020-01-13 2023-02-23 Neoimmunetech, Inc. Method of treating a tumor with a combination of il-7 protein and a bispecific antibody
US20230210952A1 (en) 2020-02-05 2023-07-06 Washington University Method of treating a solid tumor with a combination of an il-7 protein and car-bearing immune cells
EP4232070A1 (en) 2020-10-26 2023-08-30 NeoImmuneTech, Inc. Methods of inducing stem cell mobilization
US20240101629A1 (en) 2020-11-02 2024-03-28 Neoimmunetech, Inc. Use of interleukin-7 for the treatment of coronavirus
CN116615236A (zh) 2020-11-05 2023-08-18 新免疫技术有限公司 用il-7蛋白和核苷酸疫苗的组合治疗肿瘤的方法
CN116685345A (zh) * 2020-11-25 2023-09-01 杰科生物医药公司 Il-7融合蛋白及相关方法
WO2022115396A1 (en) * 2020-11-25 2022-06-02 Jecho Laboratories, Inc. Il-7 fusion protein and related methods
WO2022117569A1 (en) 2020-12-02 2022-06-09 Oncurious Nv A ccr8 antagonist antibody in combination with a lymphotoxin beta receptor agonist antibody in therapy against cancer
US20250049920A1 (en) * 2021-11-17 2025-02-13 Shanghai Juncell Therapeutics Co., Ltd. Membrane surface protein containing gpi anchor region
EP4456907A1 (en) 2021-12-30 2024-11-06 NeoImmuneTech, Inc. Method of treating a tumor with a combination of il-7 protein and vegf antagonist
WO2023133595A2 (en) 2022-01-10 2023-07-13 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
US20250222027A1 (en) 2022-04-01 2025-07-10 Sana Biotechnology, Inc. Cytokine receptor agonist and viral vector combination therapies
KR20250089492A (ko) 2022-11-07 2025-06-18 네오이뮨텍, 인코퍼레이티드 비메틸화된 mgmt 프로모터를 갖는 종양의 치료 방법
CN117050178B (zh) * 2023-10-13 2024-01-12 北京百普赛斯生物科技股份有限公司 特异性检测il-7的抗体及应用
WO2025093541A1 (en) 2023-10-31 2025-05-08 Ose Immunotherapeutics Combination of interleukin 7 and tumour associated antigen vaccine
US12605349B2 (en) 2024-09-05 2026-04-21 Orbus Therapeutics, Inc. Methods of treating grade 3 astrocytoma

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5714585A (en) * 1987-10-26 1998-02-03 Sterling Winthrop, Inc. Antibodies that are immunoreactive with interleukin-7
US5328988A (en) * 1987-10-26 1994-07-12 Immunex Corporation Interleukin-7
ZA887773B (en) * 1987-10-26 1989-07-26 Immunex Corp Interleukin-7
US4965195A (en) * 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US5728680A (en) * 1987-12-30 1998-03-17 Cytoven J.V. Methods for normalizing numbers of lymphocytes
US5459058A (en) * 1991-03-28 1995-10-17 Benjamin Rich Cell culture system
US5223408A (en) * 1991-07-11 1993-06-29 Genentech, Inc. Method for making variant secreted proteins with altered properties
WO1994022473A1 (en) * 1993-04-01 1994-10-13 University Of Washington Use of interleukin 7 to improve vaccine potency
US5696234A (en) * 1994-08-01 1997-12-09 Schering Corporation Muteins of mammalian cytokine interleukin-13
CN1269805A (zh) * 1997-07-14 2000-10-11 博尔德生物技术公司 生长激素和相关蛋白的衍生物
EP2314696A1 (en) * 1998-09-21 2011-04-27 Schering Corporation Therapeutic uses of human Interleukin-B50 antagonist.
US6749847B2 (en) * 2000-03-30 2004-06-15 The University Of Connecticut Hybrid cytokine of IL-7 and β-chain of hepatocyte growth factor
PT1699822E (pt) 2003-12-30 2008-07-30 Merck Patent Gmbh Proteínas de fusão de il-7
EP1746161A1 (en) 2005-07-20 2007-01-24 Cytheris Glycosylated IL-7, preparation and uses

Also Published As

Publication number Publication date
ATE482273T1 (de) 2010-10-15
PL213710B1 (pl) 2013-04-30
CY1110994T1 (el) 2015-06-11
IL166543A (en) 2012-02-29
CA2494974A1 (en) 2004-03-04
EP1527179A2 (en) 2005-05-04
JP2014147396A (ja) 2014-08-21
US20050249701A1 (en) 2005-11-10
WO2004018681A3 (en) 2004-04-01
US7585947B2 (en) 2009-09-08
CA2494974C (en) 2014-07-29
PL373606A1 (en) 2005-09-05
SI1527179T1 (sl) 2011-04-29
HK1075465A1 (en) 2005-12-16
ZA200501914B (en) 2005-11-30
DK1527179T3 (da) 2011-01-03
AU2003250216A1 (en) 2004-03-11
IL166543A0 (en) 2006-01-15
EP1527179B1 (en) 2010-09-22
AU2003250216B2 (en) 2010-08-05
PT1527179E (pt) 2010-12-07
WO2004018681A2 (en) 2004-03-04
JP5980467B2 (ja) 2016-08-31
JP2010115203A (ja) 2010-05-27
NO332305B1 (no) 2012-08-20
JP2005534339A (ja) 2005-11-17
ES2353006T3 (es) 2011-02-24
DE60334301D1 (de) 2010-11-04
EP1391513A1 (en) 2004-02-25

Similar Documents

Publication Publication Date Title
DK1527179T3 (da) IL-7-lægemiddelsubstans, IL-7-holdig sammensætning, fremstilling og anvendelser deraf
DK2027152T3 (da) Peptidfragmenter til induktion af syntese af ekstracellulære matrixproteiner
DE60125381D1 (de) Zusammensetzungen und verfahren mit analogen von g-csf
NO20054414L (no) Dihydropteridinoner, metoder for deres fremstilling og bruk av disse som medisiner
IL206157A (en) Pancreatic elastase protein of type 1, a nucleic acid molecule encoded by a protein
Jalil et al. Multivalent, soluble nano-self peptides increase phagocytosis of antibody-opsonized targets while suppressing “self” signaling
HRP20050585A2 (en) Peptides which inhibit angiogenesis, cell migration, cell invasion and cell proliferation, compositions and uses thereof
Hao et al. Molecular cloning, recombinant expression and antibacterial activity analysis of hepcidin from Simensis crocodile (Crocodylus siamensis)
FR2726472B1 (fr) Proteine porteuse a effet adjuvant, complexe immunogene la contenant, leur procede de preparation, sequence nucleotidique et vaccin
KR101625268B1 (ko) 여드름 개선 효과를 보이는 프로태티아마이신 항생펩타이드 유도체 및 그 용도
MXPA05011595A (es) Composiciones de spex y metodos de uso.
ATE334680T1 (de) 4-aminopiperidin-derivate, verfahren zur herstellung und ihre verwendung als arzneimittel
ATE132192T1 (de) Rekombinantes produkt
DK1947175T3 (da) Sekvens af nukleotider og peptider GSE 24,2 af dyskerin, der kan fremkalde telomeraseaktivitet, fremgangsmåde til fremstilling deraf, terapeutiske sammensætninger og anvendelser deraf
JP2021112152A (ja) バクテリオファージ由来エンドライシン
CN106478811B (zh) 虎纹蛙蛋白酶抑制肽及其基因和在制药中的应用
Musavi Motlagh et al. Improving purification of coagulation F IX using heparin affinity chromatography and its comparison with ion exchange chromatography
Li et al. Expression, purification and characterization of a novel soluble human thymosin alpha1 concatemer exhibited a stronger stimulation on mice lymphocytes proliferation and higher anti-tumor activity
AU676842B2 (en) Neutrophil stimulating peptides
ATE184287T1 (de) Derivate von therapeutisch in der blutgerinnungskaskade wirksamen peptiden, verfahren zur herstellung und sie enthaltende pharmazeutische zubereitungen
TH63184B (th) เปปไทด์ออกฤทธิ์เชิงชีวภาพ
TH77237A (th) เปปไทด์ออกฤทธิ์เชิงชีวภาพ
Huang et al. Structure-guided synthesis of melittin analogs with reduced hemolysis and enhanced anti-inflammatory activity
Shingarova et al. Novel mutants of human tumor necrosis factor with dominant-negative properties
AU2015240516A1 (en) Artificially activated peptides

Legal Events

Date Code Title Description
MK1K Patent expired